Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce ...
“Klotho” inside the body to treat neurodegenerative diseases and other diseases of aging. The Pharmaceutical Programs segment includes treatments using small drug molecules that bind to the melanocortin receptors on human cells and affect skin pigmentation and other initiatives. The company was founded...
There are two important tuning levers available to you with the PubNub JavaScript SDK for improved performance vs reduced bandwidth. Consider the compression ratio savings to latency opportunity. Withwindowingyou receive the opportunity to reduce bandwidth consumed drastically by allowing messages to be ...
Capitalization 12.62M P/E ratio 2024 * - P/E ratio 2025 * - Enterprise value 13.92M EV / Sales 2024 * 2.96x EV / Sales 2025 * 1.03x Free-Float 80.74% Yield 2024 * - Yield 2025 * - More valuation ratios * Estimated data Chart: MYCELX Technologies Corporation Period Style Dyna...
poverty would be a characteristic common to all, determinable in degree in the exact ratio of increase in population, whereas poverty is peculiarly confined to a class, and that class, as we find, the victims of capitalistic privilege and gluttony. Modern Socialists proclaim the truth that th...
Total Debt to Equity (MRQ) 203.20% Current Ratio (MRQ) 9.74 Quick Ratio (MRQ) 8.34Full Balance Sheet » PACB Cash Flow Statement Cash from Operations (TTM) -232.97M Cash from Investing (TTM) -809.00K Levered Free Cash Flow (TTM) -190.76M Unlevered Free Cash Flow (TTM) -181.87M Free...
PEG ratio (5-yr expected) -- Price/sales (ttm) 2.24 Price/book (mrq) 0.88 Enterprise value/revenue 4.49 Enterprise value/EBITDA -- Financial highlights Profitability and income statement Profit margin -211.99% Return on assets (ttm) -11.24% Return on equity (ttm) -70.57% Reven...
Total Debt to Equity (MRQ) 2.37% Current Ratio (MRQ) 1.86 Quick Ratio (MRQ) 1.82Full Balance Sheet » ACIU Cash Flow Statement Cash from Operations (TTM) 51.66M Cash from Investing (TTM) -92.38M Levered Free Cash Flow (TTM) 58.49M Unlevered Free Cash Flow (TTM) 58.59M Free Cash Flo...
Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA....
Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA....